Skip to main content

Table 1 Adequate organ function laboratory values

From: A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response

System Laboratory value
Hematological
 Absolute neutrophil count ≥1500/mcL
 Platelets ≥100,000/mcL
 Hemoglobin ≥9 g/dL or ≥5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment)
Renal
 Serum creatinine OR
Measured or calculateda creatinine clearance
≤1.5 X upper limit of normal (ULN) OR
≥60 mL/min for subject with creatinine levels >1.5 X institutional ULN
Hepatic
 Serum total bilirubin ≤1.5 X ULN OR
  Direct bilirubin ≤ULN for subjects with total bilirubin levels >1.5 ULN
 AST (SGOT) and ALT (SGPT) ≤2.5 X ULN OR
≤5 X ULN for subjects with liver metastases
 Albumin ≥25 g/L
Coagulation
 International normalized ratio (INR) or prothrombin time (PT)
Activated partial thromboplastin time (aPTT)
≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  1. aCreatinine clearance should be calculated per institutional standard